Validating Compounds for Multiple Myeloma

Objective
To bring together leading experts in compound validation from academia as well as the pharmaceutical and biotech industries to reach consensus on a single algorithm to validate a compound (or combination of compounds) for myeloma. Participants will also identify areas of weakness, as well as areas of need, in the algorithm. The MMRF will then issue requests for applications (RFAs) to the broader research community to address these areas of needs, to increase pre-clinical validation efforts in myeloma, and to promote the validation of novel and combination therapies for myeloma. To view the agenda, see the list of attendees and view photos from the meeting, click on the links below.

Sponsors
McCarty Cancer Foundation
OncoGenex
Infinity Pharmaceuticals
Keryx Biopharmaceuticals
Nereus Pharmaceuticals

View publication (pdf)

View Event Photos

View Agenda, Paricipant List, and Abstracts (pdf)